중국 정부는 5월 트럼프-시진핑 정상회담 이후 미국이 60개 이상의 중국 기업을 블랙리스트에 올림으로써 공권력을 남용했다고 밝혔다.
워싱턴 주재 중국 대사관은 미국이 베이징에서 열린 중미 정상회담에서 도출된 합의를 무시했다고 지적했다. 또한 트럼프 행정부가 국가 안보 개념을 과도하게 확장하고 국가 권력을 남용하여 중국 기업들을 부당하게 탄압함으로써 기업들의 정당한 권리와 이익을 심각하게 훼손했다고 덧붙였다. 사안에 정통한 소식통들은 사우스차이나모닝포스트(SCMP)에 최근의 상호 보복 조치가 도움이 되지 않지만, 9월로 예정된 시진핑 주석의 방미 일정에 악영향을 미칠 가능성은 낮다고 전했다. 피해를 입은 중국 기술 기업들은 국방부의 지정에 맞서 법적 대응에 나선 상태다.
AI에 의해 보고됨 AI에 의해 생성된 이미지
President Donald Trump met with Chinese leader Xi Jinping in Beijing this week for talks focused on trade, investments, and regional security issues. The two leaders discussed potential deals but made limited concrete progress.
China's Ministry of Commerce said on Saturday that Washington has abused state power by expanding a blacklist of Chinese firms under the guise of national security.
AI에 의해 보고됨
Experts say ongoing US tariff investigations against China and other trading partners are unlikely to significantly impair bilateral ties or the planned September meeting between US President Donald Trump and Chinese leader Xi Jinping.
Donald Trump said arms sales to Taiwan would be discussed during his upcoming meeting with Xi Jinping. The remarks have prompted Taipei to monitor developments closely with Washington.
AI에 의해 보고됨
President Donald Trump accused China of election-related activities aimed at undermining his first administration and 2020 campaign. The remarks came during a White House address on July 16, 2026. Administration officials later downplayed the focus on Beijing while confirming an upcoming visit by Chinese leader Xi Jinping.
The China Institutes of Contemporary International Relations released a paper on May 22 calling for peaceful coexistence between China and the US despite deepening rivalry. It warns that Washington’s position on Taiwan poses a major risk of conflict.
AI에 의해 보고됨
China’s foreign ministry announced on Monday that US President Donald Trump will pay a state visit to the country from May 13 to 15 at the invitation of President Xi Jinping. It will be the first such trip by a US president since 2017.